Zolmitriptan in the acute treatment of migraine: An overview

Reviews in Contemporary Pharmacotherapy

Volumn 11, Issue 2, 2000, Pages 91-97

  Goadsby, Peter J ^b   Peatfield, Richard ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; DRUG METABOLITE; ZOLMITRIPTAN;

ARTERY CONSTRICTION; BRAIN STEM; CAROTID ARTERY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; LIVER METABOLISM; META ANALYSIS; MIGRAINE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SPINAL CORD; TRIGEMINAL NERVE;

EID: 0034060594     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Allen C, Jiang K, Malbecq W, Goadsby PJ. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalalgia 1999; 19: 552-556.
2. Bahra A, Goadsby PJ. Chronic overuse of acute anti-migraine preparations. Prescriber 1999, in press.
3. Bax ND, Tucker GT, Lennard MS, Woods HF. The impairment of lignocaine clearance by propranolol - major effects from enzyme inhibition. Br J Clin Pharmacol 1997; 19: 597-603.
4. Castillo J, Muqoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-196.
5. Catarci T, Fiacco F, Argentino C, Sette G, Cerbo R. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 1994; 14: 374-375.
6. Catarci T, Lenzi GL, Cerbo R, Fieschi C. Sumatriptan and daily headache. J Neurol Neurosurg Psychiatry 1995; 58: 508.
7. (1B/1D) receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998; 5: 535-543.
8. Davies GM, Santanello NC, Kramer M, Matzura-Wolfe D, Lipton RB. Determinants of patient satisfaction with migraine treatment. Headache 1998; 38: 380.
9. Diener HC, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. 1st edn. New York: Raven Press, 1993: 721-727.
10. Diener HC, Klein KB for the Multinational Oral 311C90 and Sumatriptan Comparative Study Group. The first comparison of the efficacy and safety of 311C90 and Sumatriptan in the treatment of migraine. 3rd European Headache Conference. Sardinia, 5-8 June, 1996.
11. Diener HC, Pascual J, Vega P. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine. Headache 1999; 39: 351.
12. Dixon RM, Meire HB, Evans DH et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 1997; 17: 639-646.
13. Dixon R, French S, Kemp J et al. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. J Clin Pharmacol 1998a; 38: 694-701.
14. Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan. Effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest 1998b; 15: 515-522.
15. Dixon R, Engleman K, Kemp J, Ruckle JL. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol 1999; 9: 35-42.
16. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998; 5: 329-341.
17. Fanciullaci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60: 119-123.
18. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 1989; 96: 83-90.
19. Ferrari MD. Migraine. Lancet 1998; 351: 1043-1051.
20. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-294.
21. Friedman AP, Brazil P. Ergotamine tolerance in patients with migraine. JAMA 1955; 157: 881-884.
22. Gaist D, Tsiropoulos I, Sindrup SH et al. Inappropriate use of sumatriptan: population based register and interview study. Br Med J 1998; 316: 1352-1353.
23. Gallagher RM. Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine. Cephalalgia 1999; 19: 358.
24. Gallai V, Sarchielli P, Floridi A et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-390.
25. Goadsby PJ. Current concepts of the pathophysiology of migraine. In: Mathew NT, ed. Neurol Clin N Am 1997; 15: 27-41.
26. 1B/1D agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998a; 10: 271-286.
27. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psychiatry 1998b; 64: 143-147.
28. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 1993; 33: 48-56.
29. Goadsby PJ, Edvsinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994a; 117: 421-434.
30. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agaonist 311C90. Headache 1994b; 34: 394-399.
31. (1B/1D) receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996; 67: 355-359.
32. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997; 17: 153-158.
33. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-187.
34. Goadsby PJ, Gawel M, Hardebo J-E, Millson D, Bahra A, Brean S. Oral zolmitriptan is effective in the acute treatment of episodic cluster headache. Neurology 1999; 52 (Suppl 2): A257-A258.
35. Gobel H, Heinze A, Dworschak M. Easy therapeutical management of sumatriptan-induced daily headache. Neurology 1996; 47: 297-298.
36. Hill AP, Hyde RM, Robertson AD, Woolard PM, Glen RC, Martin GR. Oral delivery of 5-HT1D receptor agonists: towards the discovery of 311C90, a novel antimigraine agent. Headache 1995; 34: 308.
37. Hughes AM, Dixon R, Dane A, Kemp J, Cummings L, Yates RA. Effects of zolmitriptan (Zomig™) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Cephalalgia 1999; 19: 100-106.
38. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Wahlley ET. Serotonin and migraine. Ann N Y Acad Sci 1990; 600: 587-598.
39. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991; 11: 1-12.
40. Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR. Monitoring of acute migraine attacks: placebo response and safety data. Headache 1998; 38: 35-38.
41. Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 1978; 63: 541-549.
42. Kalbfleisch JD, Prentice RL. Marginal likelihoods based on Cox's regression and life model. Biometrika 1973; 60: 267-278.
43. Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. Br Med J 1994; 308: 1573-1574.
44. Lance JW, Goadsby PJ. Mechanism and management of headache. 6th edn. London: Butterworth-Heinemann, 1998.
45. Limmroth V, Kazarawa S, Fritsche G, Diener H-C. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999; 353: 378.
46. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30.
47. (1B/1D) receptor partial agonist for the acute treatment of migraine. Eur J Pharmacol 1998; 361: 191-197.
48. 1D receptor agonist 311C90. New Adv Headache Res 1994; 4: 3-4.
49. 1B/1D agonist for migraine. Cephalalgia 1997; 17 (Suppl 18): 4-14.
50. (1B/1D) receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121: 157-164.
51. Mauskop A, Pfaffenrath V, Tepper S. Zolmitriptan: reliable relief of migraine symptoms with early onset of action. 41st Scientific Meeting of the American Association for the Study of Headache. Boston, MA, 11-13 June, 1999.
52. Mercer AJ, Lamb RJ, Rolan PE, Gibbens M, Posner J. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers. Psychopharmacology Berl 1998; 140: 398-404.
53. Myllyla VV, Havanka H, Herrala L et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparative effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998; 38: 201-207.
54. Nilsson T, Longmore J, Shaw D et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999; 372: 49-56.
55. Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7: 468-478.
56. Peck RW, Seaber EJ, Dixon R et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol 1997; 44: 595-599.
57. (1B/1D)-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 1998; 63: 342-353.
58. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31: 295-299.
59. (1B/1D) agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17: 849-854.
60. Rapoport AM, Ramadan NM, Adelman JU et al. on behalf of The 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 1997; 49: 1210-1218.
61. Schoenen J, Jones M, Kane K, vanAssche P, Saiers J. Naratriptan 2.5 mg tablets have similar efficacy in the acute treatment of migraine as zolmitriptan 2.5 mg tablets, but exhibit a longer duration of action and are better tolerated: results of a comparator study. Neurology 1999; 52 (Suppl 2): A257.
62. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996; 41: 141-147.
63. Seaber E, On N, Dixon RM et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997a; 43: 579-587.
64. Seaber EJ, Gillotin C, Mohanlal R, Layton G, Posner J, Peck R. Lack of interaction between pizotifen and the novel antimigraine compound zolmitriptan in healthy volunteers. Clin Drug Invest 1997b; 14: 221-225.
65. Seaber EJ, Ridout G, Layton G, Posner J, Peck RW. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol 1997c: 53: 299-234.
66. Seaber EJ, Peck RW, Smith DA et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1998; 46: 433-439.
67. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacol 1995; 34: 255-261.
68. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. 1st edn. Oxford: ISIS Medical Media, 1998.
69. Smith DA, Cleary EW, Watkins S, Huffman CS, Dilzer SC, Lasseter KC. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. J Clin Pharmacol 1998a; 38: 685-693.
70. Smith DA, Cleary EW, Watkins S, Huffman CS, Polvino WJ. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther 1998b; 36: 301-305.
71. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of The 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219-1225.
72. Soons PA, De Boer A, Cohen AF, Breimer DD. The assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. Br J Pharmacol 1991; 32: 697-704.
73. (1B/1D) agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120: 2171-2177.
74. Terzoudi M, Kavvadia E, Tagaris GA, Spantideas A, Karegeorgiou K. A comparative study of the effectiveness of sumatriptan, zolmitriptan and acetylsalicylic lysine in migraine attacks, in the emergency room. Cephalalgia 1999; 19: 362.
75. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared to oral sumatriptan for migraine. Lancet 1995; 346: 923-926.
76. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine - a review and European consensus. Brain 1999, in press.
77. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38: 173-183.
78. The Oral Sumatriptan and Aspirin Plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32: 177-184.
79. Thomsen LL, Dixon R, Lassen LH et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996; 16: 270-275.
80. Veronese L, Gillotin C, Mario Gallois R et al. Lack of interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan in healthy volunteers. Clin Drug Invest 1997; 14: 217-220.
81. Visser WH, Burggraaf J, Muller LM et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996a; 60: 452-460.
82. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996b; 16: 264-269.
83. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996c; 46: 522-526.
84. Weitzel KW, Thomas ML, Small RE, Goode JVR. Migraine: a comprehensive review of new treatment options. Pharmacotherapy 1999; 19: 957-973.
85. Werhahn KJ, Forderreuther S, Straube A. Effects of the serotonin (1B/1D) receptor agonist zolmitriptan on motor cortical excitability in humans. Neurology 1998; 61: 896-898.